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Summary.-Serum complement levels were assayed in26 patients with disseminated
cancer, who received immunotherapy with infusion of C. parvum. Complement
activation, indicated by the consumption of C3 or C4 or both, was found in 46°' of the
patients.
SerumsamplesshoweddirectcorrelationbetweendecreasedC3andconversionofC3
proactivator, whereas such conversion did not occur when C4 alone was decreased.
It is concluded that the bypass (properdin) pathway was activated in patients in whom
C3 consumption was detected, while the classical (Cl) pathway was activated in the
patients with C4 consumption unaccompanied by C3 decrease. Direct correlation
was observed between delayed cutaneous hypersensitivity reactions to recall antigens
and the incidence of C. parvum-associated complement activation.
CLINICAL interest in the immuno-
therapeutic potential of the anaerobic
bacterial species Corynebacterium parvum
(C. parvrum) was stimulated by the
demonstration in animal models that C.
parvum augments resistance to infections
(Adlam, Broughton and Scott, 1972;
Halpern et al., 1973) and protects against
graft-versus-host disease (Howard et al.,
1967). Administration of C. parv,um may
prevent tumour engraftment (WA'oodruff
and Boak, 1966), prolong survival (Hal-
pern et al., 1966), or induce long-lasting
regression of established tumours (Likhite
and Halpern, 1974) in animals.
The recent demonstration in mice of
regression of Lewis lung carcinoma meta-
stases following parenteral administration
of C. parvrum (Milas et al., 1974), has
prompted clinical trials ofimmunotherapy
with C. parrurn in metastatic human
cancer (Band et al., 1975; Reed et al.,
1975).
Infusion of C. parrrun into the circu-
lation might be expected to activate the
C3 bypass (properdin) pathway (Gotze and
Muller-Eberhard, 1971) by virtue of bac-
terial-wall polysaccharide and lipopolysac-
charide constituents (Gewurtz, Shin and
Morgenhagen, 1968).
Since naturally occurring antibodies
to C. parvum may circulate in cancer
patients (James et al., 1975), i.v. C. parvrum
may result in the immediate formation of
antigen-antibody complexes capable of
activating the Cl (classical) pathway
(Ruddy, Gigli and Austen, 1972).
Additionally, following repeated anti-
genic stimulation by i.v. C, parvum,
specific antibody production may result in
immune complex-induced activation ofC1.
Recently, it has been demonstrated
that complement components are acti-
vated when C. parrum is added to guinea-
pig or human serum in vitro (McBride et
al., 1975).
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The present study was designed to
determine ifcomplement activation occurs
in vivo in cancer patients receiving
immunotherapy with C. parvum.
MATERIALS AND METHODS
Twenty-six patients with disseminated
cancer who had been selected for a Phase I
trial of i.v. C. parvum immunotherapy were
evaluated for C. parvum-associated comple-
ment activation.
Clinical and histological diagnoses were:
melanoma (16 patients), acute leukaemia (3),
colon carcinoma (3), lung carcinoma (2),
lymphoma (1), and carcinoid (1).
Patients received killed, endotoxin-free
(Limulus test negative) C. parvum suspensions
(Burroughs Wellcome Research, Triangle
Park, North Carolina) during intervals be-
tween courses of chemotherapy.
Each immunotherapy treatment consisted
of a single i.v. C. parvum dose. Individual
doses of C. parvum, ranging from 1 to 10
mg/M2, were infused over 1-h periods. The
same C. parvum dosage was maintained
throughout the treatment course for each
patient.
In order to evaluate serum complement
changes, each patient was followed at
sequential C. parvum treatments, and served
as his own control. For complement com-
ponent determination, venous blood samples
were obtained before, and 2 h after, the
completion of each C. parvum infusion.
Serum was separated within 30 min and
stored at - 70°C.
Serum levels of C4 and C3 were deter-
mined by haemolytic assays, as previously
described (Vroon, Schultz and Zarco, 1970;
Moake and Schultz, 1975). Cellular inter-
mediates (EACI, EAC1-4) and complement
components (C2, C5-9) were obtained from
Cordis Laboratories, Miami, Florida. Indi-
vidual and pooled normal serum samples
were always included as controls. The titre
of the control samples ranged as follows:
C3 (mean : s.d.) 26,100 ± 21,500; C4,
92,400 ± 43,600, CH50 u/ml.
Complement activation was considered to
have occurred if there was at least a four-fold
decrease in serum titres ofC4 or C3 (or both),
as compared to pre-C. parvum levels. If a
four-fold (2 tubes dilution difference) or
greater decrease in haemolytic titre was
observed during the time interval between the
completion of one C. parvum infusion and the
subsequent infusion, complement activation
was considered to have occurred in the
absence of evidence for intervening infection
(Fearon et al. 1975).
This late activation was considered to be
"delayed ". Complement activation detec-
ted within 2 h following C. parvurn infusion
was defined as " immediate ".
Conversion of the C3-proactivator (C3PA)
to its activated form (C3A) was determined
by immunoelectrophoresis as previously
described (Wands et al., 1975). Fresh normal
human serum (NHS) and zymozan-activated
NHS served respectively as negative and
positive controls. Appearance in tested
serum of C3A with gamma mobility, similar
to that seen in zymozan-activated NHS,
indicated activation of C3 proactivator.
Anti-C3 activator was obtained from Behring-
werke AG., Marburg-Lahn, West Germany.
While on C. parvurm immunotherapy the
patients' cell-mediated immunocompetence
was evaluated by skin testing with recall
antigens (Dermatophytin, Dermatophytin-0,
Varidase, Candida, Mumps and PPD), and by
primary sensitization to Keyhole Limpet
Haemocyanin (KLH) and to dinitro-chloro-
benzene (DNCB) (Gutterman et al., 1973).
Positive reaction to at least 2 recall antigens
of5-mm induration was required for a patient
to be classified as " recall antigen positive ".
Statistical analysis of the correlation
between complement activation and delayed
hypersensitivity skin reactions was performed
by the x2 test.
RESULTS
Theincidenceofimmediate anddelayed
complement consumption relative to the
number of patients and to the total
number of C. parvum infusions is shown
in Table I. Complement component con-
sumption was detected in 12 (46%) of 26
patients. In 11 of these 12 patients,
consumption was of the immediate type.
Of 60 total C. parvum infusions, 16
(26.6%) were followed by complement
consumption of either the immediate (12)
or delayed (4) type. C4 or C3 components
were consumed following 14 of 60 C.
parvum infusions (Table II). Both C4
and C3 were simultaneously consumed
after 2 infusions. Immediate and de-
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TABLE I. Incidence of Complement Activation and its
Time of Occurrence Following i.v. C. parvum
Number
26
60
Occurrence of complement activation
Immediatea Delayedb Overall
11 (42 *3%) 1 (3 *8%) 12 (46*1%)
12 (200%o) 4 (6 60') 16 (26 6%)
a Immediate detected withi.n 2 h after completion of C. parr-um
infusion.
b Delayed detected during the time interval between 2 consecutive
C. parvum treatments, excluding the first 2 h.
TABLE II. The Activation of Specific
Complement Components Following 60
i.v. C. parvum Treatments
Incidence of C. parvurn-associated
complement activation
Activated ----_--A
component(s) Immediatea Delayedb Overall
C4
C3
C4 + C3
4
6
2
3
1
0
7
7
2
a Immediate detected within 2 h after com-
pletion of C. parvuum infusion.
b Delayed detected during the time interval
between 2 consecutive C. parvum treatments,
excluding the first 2 h.
layed consumption was almost equal for
C4, whereas C3 consumption was pre-
dominantly of the immediate type. The
4 instances of delayed consumption oc-
curred 1-13 days (median = 7 days) after
C. parvum administration.
C4 consumption following the first
treatment of C. parvum was observed in
3 patients, whereas consumption ofC3 was
only observed subsequent to the second
C. parvum treatment and thereafter
(Table III).
Complement consumption was repeat-
edly demonstrated in 4 patients. In all
ofthese, C4 consumption preceded that of
C3. Concomitant consumption of C4 and
C3 was detected in only 2 instances and
did not occur before the fifth C. parvum
infusion. No correlation could be demon-
strated between the dose of C. parvutm
infused and the incidence or degree of
complement consumption (Table IV).
Also, no dose-related differences were
observed between C4 vs. C3 consumption.
Following consumption, complement com-
ponent levels were subsequently restored
to normal levels within 7 to 36 days
(median 20 days).
Nine serum samples of patients in
whom complement consumption had
occurred were assayed for the presence of
C3PA and its activated form, C3A. As
shown in Table V, conversion to the acti-
vated form occurred when C3 was con-
sumed. In contrast, consumption of C4,
unaccompanied by that of C3, was not
associated with conversion of the pro-
activator. In the category of concomitant
TABLE III.-Incidence of Complemnent Component Activation Following Infusion
of C. parvum according to Serial Treatment Number
Complement No. of instances/No. of treatments
component(s)
activated Treatment number
1 2 3a 4 5 6 7 8 9 10
C4 3/16 2/15 1/5 0/7 0/6 1/4 0/3 0/2 0/1 0/1
C3 0/16 3/15 0/5 2/7 0/6 0/4 0/3 0/2 1/1 1/1
C4 + C3 0/16 0/15 0/5 0/7 1/6 1/4 0/3 0/2 0/1 0/1
An.fiv-i. n
Incidence per
treatment 3/16 5/15 1/5 2/7 1/6 2/4 0/3 0/2 1/1 1/1
a Although the number of patients receiving a 3rd C. parvum treatment was higher, complement was
evaluated in only 5.
34
Category
Patients
Treatments
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TABLE IV. Complement Activation in
Patients Receiving V'arious Dose Levels
of C. parvum
Patients with
Dose No. of complement
mg/ml patients activation
1
2
3
5
7 5
10
4
3
10
6
2
0
3
1
3
0
TABLE V.-The Relationship between the
OccurrenceofC3Proactivator Conversion
and the Status of C4 and C3 Comnponents
following C. parvum Administration
Status of complement
components
(a) Low C3 with normal C4
(b) Low C3 with low C4
(c) Normal C3 with low C4
Conversion
C3PA-+C3A
Positive/Tested
3/3
1/2
0/4
C3 and C4 consumption, clear conversion
was demonstrated in one case and a faint
band with C3A mobility was detected in
the other case.
Both complement activation and de-
layed hypersensitivity skin reaction were
studied in 15 patients. In these 15,
complement activation was detected in 8.
All 8 reacted positively to at least 2 recall
antigens (Table VI).
In 7 patients with no demonstrable
C. parvum-associated complement acti-
vation only 2 had positive reactivity to
TABLE VI.-Relationship between Comple-
ment Activation and Delayed Hyper-
sensitivity Skin Reactions in Cancer
Patients Receiving Immunotherapy with
C. parvum
Patients with (iclayed skin
hypersensitivity to:
Complement Recall
status Antigensa PPD KLH DNCB
Activated 8/8b 5/8 5/8 7/8
Not activated 2/7 3/7 2/7 4/7
a Delayed hypersensitivity present if patienit
reactive to at least 2 of the antigens.
bP < 0.*05
recall antigens (P < 0.05). No apparent
relationship was observed between re-
activity to PPD, KLH or DNCB and
complement activation. The survival,
from initiation of C. parvum therapy, of
patients whose serum complement was
activated, was slightly, but not signifi-
cantly, longer than that of patients in
whom complement activation was not
detected (median survival: 6 months for
the former, 5 months for the latter group;
P > 0 05, by the general Wilcoxon test).
DISCUSSION
The results of this study indicate that
i.v. administration of C. parvum induces
consumption of complement components
in a substantial proportion of patients
withdisseminated cancer. Inthemajority
of cases, complement component con-
sumption consistently showed a close time
relationship to C. parvum administration,
and there was no evidence for induction of
complement activation by factors other
than C. parvrum. In the few cases where
activation was delayed 1-13 days (median
7 days) we cannot exclude the theoreti-
cal possibility that the phenomenon was
not C. parvum-related. Either the " clas-
sical " (CI, 2, 4) or the C3 bypass (proper-
din) pathway may be activated. The
association between C3 consumption and
the conversion of C3PA to its activated
form, as opposed to lack of such conver-
sion when only C4 was consumed in the
sampled sera, supports the contention that
isolated C4 consumption reflects classical
pathway activation (Cooper, 1973), where-
as C3 consumption indicates activation of
the bypass pathway following C. parvrum
infusion. Complementactivationthrough
the classical pathway is usually induced by
C1 attachment to IgM, IgG1, IgG2 or IgG3,
after the formation of antigen-antibody
complexes (Ruddy et al., 1972). Such
complex formation may follow i.v. admini-
stration of C. parvum, since naturally
occurring antibodies to C. parvum have
been demonstrated in humans (James et
al., 1975) as well as in mice (McBride et al.,
1975; Woodruff, McBride and Dunbar,
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1974). Furthermore, anti-C. parrum anti-
body responses have been described in
cancer patients treated with parenteral
C. parvumr. The immunoglobulin res-
ponses were primarily of IgG type and
consisted mainly of the JgG2 and IgG1
sub-classes (James et al., 1975). Con-
sequently, single or repeated C. parvum
infusion may result in circulating antigen-
antibody complexes and activation of the
classical complement pathway through
C11. Consumption of C4 immediately
following the first C. parvum treatment,
observed in some of our patients, is con-
sistent with the presence of pre-existing
circulating antibodies to C. parvrum and
activation of complement through the
classical pathway. The occurrence of
classical pathway activation only in a
portion of the studied patient population
could be explained by possible variation
in the level of circulating anti-C. parvum
antibodies inthispopulation. This factor,
combined with the variation in C. parrum
dose administered, would result in variable
antigen: antibody ratio and consequently,
different conditions for formation of
circulating immune complexes in different
individuals. In other patients, properdin
pathway activation, detected after C.
parvam infusion may have been induced
by C. parvuni cell-wall polysaccharide
(Dawes, Tuach and McBride, 1974).
V'arious bacterial and fungal polysac-
charides andlipopolysaccharides have been
shown to activate the properdin pathway
((ewurtz et al., 1968; Gotze and Muller-
Eberhard, 1971). This direct effect may
be inversely related to the capacity of the
reticulo-endothelial system (RES) to re-
move C. parrum organisms from the
circulation (Fearon et al., 1975). Vari-
able RES capacity to clear particulate
matter, which can be either enhanced by
stimulants such as C. parrum (Halpern et
al., 1973) or blocked by excessive load of
repeatedly infused stimulant or other
phagocytosed material, could account for
the incidence of bypass (properdin) acti-
vation, as observed in this studv. Since
circulating antigen-antibody complexes
may also be removed by the RES, the
observed incidence of Cl pathway acti-
vation could have been affected by this
factor as well. Recently, a decrease in
serum C3 level after completion of i.v.
C. parvrum therapy in patients with
disseminated cancer has been reported
(Israel et al., 1975).
C. parvrum treatment, delayed hyper-
sensitivity and complement activation,
may all be linked to macrophage acti-
vation. There is a growing body of
evidence suggesting that C. parvrum acti-
vates macrophages, andthese are currently
believed to mediate some of its anti-
tumour effects (Ghaffar, Cullen and Wood-
ruff, 1975; Olivotto and Bomford, 1974;
Wolmark and Fisher, 1974). Second,
macrophage infiltration is a major com-
ponent of delayed hypersensitivity skin
reactions (Dannenberg, 1975). Third,
macrophages may also interact with
complement by virtue oftheircomplement
receptors (Rowlands and Daniele, 1975).
It has been suggested that C3 decrease
observed in cancer patients after repeated
C. parvrum infusions may be due to
increased consumption byactivated macro-
phages (Israel et al., 1975). Such a
mechanism could operate in those of our
patients whose complement components
consumption was delayed, but it is
unlikely to account for C4 or C3 consump-
tion when it occurred immediately follow-
ing C. parvum infusion. Of particular
interest is the evidence, reported very
recently, that activated complement com-
ponents (e.g. C3b) can induce lysosomal
enzyme release from macrophages in vitro
(Schorlemmer, Davies and Allison, 1976).
Ifthis is true in vivo it could help elucidate
the mechanism by which macrophages are
activated by C. parrum.
In addition to macrophages, bone-
marrow-derived lymphocytes may also be
involved in the complex of cellular and
humoral immunological reactions trig-
gered by C. parvrum since they are also
activated by this immunotherapeutic
agent (Howard, Scott and Christie, 1973).
Some bone-marrow-derived lymphocytes
497498 H. BIRAN ET AL.
carry complement receptors (Jaffe et al.,
1974) and may, upon interaction with
complement, liberate certain lymphokines
(Wahl, Iverson and Oppenheim, 1974).
The latter, prepared in vitro and injected
into tumour nodules, have been recently
shown to augment delayed hypersensiti-
vity and induce tumour regression (Klein,
et al., 1975).
Survivalanalysis comparing C.parvum-
treated patients according to whether
serum complement was activated or not,
showed only slight advantage associated
with complement activation, with no
statistical significance. However, only
patients with advanced metastatic disease
were included in this Phase I study, and
therefore projection cannot be made from
this study on the possible effect of C.
parvum-associated complement activation
on survival of patients with less advanced
cancer.
Complement has recently been shown
to form complexes with antibodies on the
surface of human cancer cells in vivo
(Irie, Irie and Morton, 1975). Also, it is
noteworthy that some polysaccharides
with anti-tumour activity have been
reported to activate complement in vitro
(Okuda et al., 1972). Furthermore,
quantitative correlation has been demon-
strated between C3-activating capacity
in vitro and the protection conferred in
vivo by the same polysaccharides against
tumour transplantation (Nishioka, 1975).
It is conceivable that under different
circumstances (i.e., less advanced disease)
C. parvum-associated complement acti-
vation may play an important role in the
host defence against the tumour.
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